Relevance: Novo Nordisk, the drug’s developer, announced the study’s topline results in a press release. On average, participants experienced a 15.1% decrease in weight after receiving the medication, regardless of treatment adherence, compared with a 2.4% weight loss with the placebo. The amount of weight loss with oral semaglutide was...
Share
Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37254688/
Among adults with obesity or overweight, semaglutide and phentermine/topiramate were associated with greater body weight loss and waist circumference reduction at 12 months than all other drugs, and lower or...
Conclusions: Among adults with obesity or overweight, semaglutide and phentermine/topiramate were associated with greater body weight loss and waist circumference reduction at 12 months than all other drugs, and lower or no significant difference in risks of withdrawal. There was no evidence that drugs approved for weight management had...
Share
Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37256503/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: In PIONEER 1-5 and 8, odds of achieving clinically relevant reductions in both HbA1c and body weight were significantly greater with orally administered semaglutide versus comparators.
Share
Effects of GLP-1 receptor agonists on neurological complications of diabetes - Reviews in Endocrine and Metabolic Disorders
Source : https://link.springer.com/article/10.1007/s11154-023-09807-3
Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy....
Conclusions/Relevance: GLP-1 RAs are promising drugs that seem to be useful in the reduction of some neurological complications of diabetes. However, more studies are needed.
Share
A systematic review of the economic value proposition for commercially available nonsurgical weight-loss interventions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37231621/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Evidence of cost-effectiveness for commercially available, evidence-based, nonsurgical weight-loss interventions is mixed. There is no evidence for cost-saving weight-loss medications and only weak evidence for behavioral and weight-loss interventions. Results provide a call to action to generate more robust evidence of the...
Share